Dysfunction of the host immune system can be detected in many patients with different cancer types, and contributes to tumor escape and failure of therapies that aim to elicit or boost anti-tumor immunity. Yet, immune-mediated tumor rejection and long term cancer control have been documented in a minority of patients. A better understanding
